The FSHD Industry Collaborative is a first-of-its-kind, multi-stakeholder initiative designed to improve how FSHD clinical trials are designed, executed, and evaluated RANDOLPH, Mass. and VANCOUVER, BC, April 8, 2026 /PRNewswire/ — The FSHD Society, a patient-driven organization advancing research and clinical development in facioscapulohumeral muscular dystrophy (FSHD), SOLVE FSHD, a venture philanthropic organization dedicated to accelerating treatments …
VANCOUVER, British Columbia–(BUSINESS WIRE)–SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), today announced grant funding awarded following its 2025 Request for Proposals. SOLVE FSHD will provide funding to leading clinician scientists validating biomarker assays and clinical outcome frameworks in FSHD, with the intent to share the results with the …
Vancouver, BC & Tokyo & Waltham, Mass. – SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; “Modalis”), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting …
GAITHERSBURG, Md.–(BUSINESS WIRE)–Mirecule, Inc., a leader in Antibody RNA Conjugate (ARC) therapeutics targeting rare neuromuscular diseases, today announced an expansion of its strategic collaboration with Sanofi. This collaboration focuses on delivering transformative treatments for patients with Facioscapulohumeral Muscular Dystrophy (FSHD). Building upon the companies’ successful partnership in developing ARC therapies, the expanded agreement will facilitate …
Company to present at J.P. Morgan Healthcare Conference on Tuesday, Jan 13, 2026 SAN FRANCISCO–(BUSINESS WIRE)–Epicrispr, a clinical-stage company pioneering gene-modulating therapies, today reported early clinical data from its ongoing first-in-human, open-label study evaluating EPI-321, an investigational epigenetic therapy for facioscapulohumeral muscular dystrophy (FSHD). Epicrispr holds the first and only open epigenetic editing Investigational New …
− First patient with facioscapulohumeral muscular dystrophy (FSHD) dosed with Restem-L umbilical lining modified progenitor cells (UMPCs) − The Phase 1/2a study will evaluate the safety and preliminary efficacy of Restem-L in patients with FSHD − Clinical study is funded by SOLVE FSHD MIAMI and VANCOUVER, British Columbia, Dec. 08, 2025 (GLOBE NEWSWIRE) — RESTEM …